



# MINDMED CORPORATE UPDATE

## 07.02.2020






MindMed

# MindMed Corporate Update

Transformative medicines that address big problems in society.



NEO: MMED  
OTCQB:MMED  
DE:MMQ

July 2020

MindMed.co

# Webcast Disclaimer

This webcast of Mind Medicine (MindMed) Inc. on July 2, 2020 contains "forward-looking information", which may include, but is not limited to, statements with respect to anticipated business plans or strategies of MindMed, the anticipated date of completion of micro-dosing studies, the timing of any drug trials, the success of its clinical trials, the ability to enter into acquisitions or collaborations to enhance its drug development platform, the success of any such acquisitions or collaborations and the ability to use the information relating to, or obtain patents or other intellectual property protection on, data and clinical trials generated directly by MindMed or through such acquisitions or collaborations, and the success or stage of development of discoveries or medicines. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MindMed to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in MindMed's management's discussion and analysis for the period from May 30, 2019, date of incorporation, to December 31, 2019 ("MD&A"), dated March 30, 2020, which is available on MindMed's website and the company's profile at [www.sedar.com](http://www.sedar.com). Forward-looking statements contained herein are made as of the date of this webcast and MindMed disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management's estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the listener is cautioned not to place undue reliance on forward-looking statements.

# Estimated \$100 billion annual total addressable market for psychedelics



Anxiety

40m<sup>1</sup>

U.S. Adults affected by anxiety

ADHD

10m<sup>2</sup>

U.S. Adults use stimulant prescription medicines.

Addiction

20m<sup>3</sup>

Americans w/ Substance Abuse Disorders

Depression

17m<sup>4</sup>

Adults with major depression

# Building a business in psychedelics = building a drug development company

## Rigorous Scientific Research Underway On Psychedelics As MEDICINES

- LSD
- Psilocybin (Mushrooms)
- MDMA
- DMT
- Mescaline
- 5-meo-dmt



## A Psychedelic Inspired Medicine Has Already Been Approved

### SPRAVATO (Esketamine)

Approved Psychedelic by FDA  
(Treatment Resistant Depression)



**=\$1.5 Billion USD<sup>7</sup>**


Estimated peak sales



# Our Process

Discover. Develop. Deploy


Current MindMed 2020 Position



Capital Intensive  
Deploy

Develop

Capital Efficient - Potential Pharma Partners  
Faster Time to Market - Strategic Acquisitions



Long time to market  
Discover

# Discover. Develop. Deploy

Phase 2 trials MindMed is pursuing

Anxiety

LSD

ADHD  
LSD Microdosing

Cluster Headaches

LSD


Addiction

18-MC



# Industry Leading Development Portfolio

## Clinical Trial Status Update





# MindMed Is Pioneering A New Asset Class in Medicine Based on Psychedelics

## Non-Hallucinogenic Therapies



Derived from psychedelics, zero to negligible hallucination effect



Doctor prescription




Pharmacy pickup, take-home




## Hallucinogenic Therapies



A high dose or experiential dose of psychedelics



Direct supervision and therapy session overseen by therapist & doctor




In-clinic treatment only



# MindMed is developing BOTH

## Non-Hallucinogenic Therapies

LSD - Microdosing



ADHD: \$9.1 billion<sup>3</sup>




Addiction: \$42 billion<sup>4</sup>


18-MC  
(ibogaine derivative)

## Hallucinogenic Therapies

LSD - Experiential Anxiety



Anxiety: \$4.5<sup>3</sup>



Depression: \$4 billion<sup>3</sup>



# Non-Hallucinogenic Program Updates

- Microdosing LSD
- 18-MC

# Addiction Division - Opioid Use Disorder

Phase 1b / Phase 2 Ibogaine Derivative 18-MC



## Updates

- Phase 1b underway in Australia amidst COVID-19
- Phase 2 projected to begin by end of Q4 in Opioid Withdrawal patients
- Ongoing discussions w/ KOLs on Phase 2 and regulatory experts

# Microdosing Division - Adult ADHD

## Phase 2a Using Small Amounts of LSD

### Program UPDATES

- Phase 2a looking for proof evaluating if LSD can increase focus in adults, Q4 target start date
- 2 trial sites : Maastricht (Netherlands) and University Hospital Basel (Switzerland)
- Leading global researcher in microdosing Dr Kim Kuyper acting as Co-Pi with Dr Matthias Liechti



# Hallucinogenic / Experiential Program Updates

- Project Lucy (LSD- Anxiety Disorders)
- Cluster Headaches (LSD)

# Project Lucy - Anxiety

## Experiential Therapy

### Phase 2b Using LSD



## Program Updates

- MindMed acquired Phase 2 Anxiety clinical trial from UHB ongoing since 2017 by Dr Peter Gasser
- MindMed intends to use readout from this Phase 2 study as basis for opening a Phase 2b clinical trial w/ FDA
- Currently preparing pre-IND meeting and briefing package

# Cluster Headaches

Phase 2 LSD Trial for "Suicide Headaches"



## Program Updates

- Phase 2a Began Treating Patients in Q2 at University Hospital Basel
- LSD pulse regimen (3 x 100 µg LSD in three weeks) in 30 patients
- Evaluating Orphan Drug Potential



# R&D and IP Update

- UHB Liechi Lab Collaboration
- LSD & MDMA Data Acquisitions
- New IP
- Phase 1 studies

# Liechti Lab Collaboration

## LSD Clinical Trials

- Pharmacokinetics
- PK-PD Analyses
- Long term effects

4 X Phase 1 Trials (Completed)

1 X Phase 1 Trials (Ongoing)

3 X Phase 2 Trials (Ongoing)

## MDMA Clinical Trials

Acquired exclusive world wide license to largest portfolio of Human Safety Data and Phase 1 trials on MDMA



**University Hospital  
Basel**




# Next-Gen R&D

LSD Neutralizer - Enabling Control  
Filed patent application



Tech-enabled Personalized Medicine

Dose Optimizer for Personalized Medicine  
Filed patent application




Shorten and Stop LSD Trips

# Next-Gen R&D

DMT - Active ingredient in Ayahuasca  
Phase 1 clinical trial of DMT



MDMA - Advanced Trial Data, MDMA+LSD  
9 completed clinical trials of MDMA



Coveted portfolio additions

# Corporate Development

## Key Additions, Promotions, Partnerships Last Quarter

Matthew W. Johnson, Ph.D.



Jeanne Bonelle  
EVP



Professor Dr. Matthias Liechti



## Strategic University Partnerships



Phase 2a clinical trial for **LSD** in adult patients with ADHD



Partnership, clinical trial acquisition, and collaboration



Discover. **Develop.** Deploy.



# MINDMED CORPORATE UPDATE

## 07.02.2020





MindMed

# Thank you!

Get on our list for all the latest updates:

Register for MindMed's Newsletter

[www.mindmed.co](http://www.mindmed.co)

[invest@mindmed.co](mailto:invest@mindmed.co)

Corporate Presentation  
[www.mindmed.co](http://www.mindmed.co)